Tevogen Bio Holdings Inc.
Business
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company developing off-the-shelf, allogeneic CD8+ cytotoxic T cell therapies using its proprietary ExacTcell platform technology. The company's lead product, TVGN 489, is an allogeneic T cell therapy designed to treat COVID-19 in immunocompromised and high-risk elderly patients, with additional development for Long COVID and other viral infections. The company is also advancing a pipeline of product candidates targeting HPV-related cancers, hepatitis B, Epstein-Barr virus-associated diseases, and other oncologic indications through its precision T cell technology platform.
Summary from 10-K filed 2026-03-31
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Research and development | 11 | 31 | 4 | — | |
| General and administrative | 15 | 23 | 4 | 953,083 | |
| Total operating expenses | 26 | 54 | 9 | — | |
| Loss from operations | −26 | −54 | −9 | — | |
| Interest expense, net | −195,618 | −184,037 | — | — | |
| Merger transaction costs | — | −7 | — | — | |
| Change in fair value of warrants | 60,701 | −58,180 | — | 413,250 | |
| Change in fair value of convertible promissory notes | — | 48 | −50 | — | |
| Loss on issuance of commitment shares | — | −890,000 | — | — | |
| Net loss | −26 | −14 | −60 | 4 | |
| Net loss attributable to common stockholders, basic | −27 | −10 | −60 | — | |
| Net loss attributable to common stockholders, diluted | −27 | −10 | −60 | — | |
| Net loss per share attributable to common stockholders, basic | −8.08 | −3.5 | −2.44 | — | |
| Net loss per share attributable to common stockholders, diluted | −8.08 | −3.5 | −2.44 | — | |
| Weighted-average common stock outstanding, basic | 3 | 3 | 25 | — | |
| Weighted-average common stock outstanding, diluted | 3 | 3 | 25 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash | 552,372 | 1 | 1 | 129,186 | — | |
| Prepaid expenses and other assets | 828,592 | 919,088 | 670,582 | 145,170 | 446,610 | |
| Total current assets | 2 | 2 | 2 | 274,356 | 791,191 | |
| Property and equipment, net | 170,308 | 296,442 | 458,651 | — | — | |
| Right-of-use assets - operating leases | 1 | 228,490 | 469,862 | — | — | |
| Deferred transaction costs | 183,546 | — | 3 | — | — | |
| Other assets | 1 | 575,841 | 271,141 | — | — | |
| Total assets | 4 | 3 | 6 | 357 | 353 | |
| Accounts payable | 3 | 5 | 3 | — | — | |
| Accrued expenses and other liabilities | 1 | 2 | 1 | — | — | |
| Operating lease liabilities | 327,740 | 229,063 | 252,714 | — | — | |
| Notes payable | 2 | 2 | — | — | — | |
| Total current liabilities | 7 | 9 | 85 | 350,454 | 59,375 | |
| Loan agreement | 4 | 1 | — | — | — | |
| Operating lease liabilities | 1 | 5,796 | 234,858 | — | — | |
| Derivative warrant liabilities | 26,479 | 87,180 | — | — | — | |
| Total liabilities | 13 | 10 | 100 | 15 | 15 | |
| Common stock, $0.0001 par value; 800,000,000 shares authorized; 4,020,746 and 3,559,827 shares issued and outstanding at December 31, 2025 | 402 | 356 | 12,000 | — | — | |
| Additional paid-in capital | 123 | 98 | 5 | — | — | |
| Accumulated deficit | −140 | −113 | −100 | −15 | −14 | |
| Total stockholders deficit | −8 | −7 | −94 | −34 | −14 | |
| Total liabilities and stockholders deficit | 4 | 3 | 6 | 357 | 353 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Depreciation expense | 190,573 | 162,209 | 163,300 | — | |
| Stock-based compensation expense | 16 | 41 | — | — | |
| Non-cash interest expense | — | 187,575 | 1 | — | |
| Merger transaction costs | — | 7 | — | — | |
| Loss on Series A Preferred Stock issuance | — | 799,990 | — | — | |
| Amortization of right-of-use asset | 318,624 | 241,372 | 215,057 | — | |
| Prepaid expenses and other assets | 101,838 | −246,005 | −317,605 | 446,609 | |
| Other assets | −490,043 | −511,011 | 323,742 | — | |
| Accounts payable | −2 | 2 | 1 | — | |
| Accrued expenses and other liabilities | −74,203 | −681,450 | −603,832 | — | |
| Operating lease liabilities | −297,976 | −252,713 | −223,361 | — | |
| Net cash used in operating activities | −12 | −12 | −8 | −215,395 | |
| Purchases of property and equipment | −64,439 | — | −133,000 | — | |
| Net cash used in investing activities | −64,439 | — | −133,000 | — | |
| Cash acquired in connection with the reverse recapitalization | — | 229,328 | — | — | |
| Proceeds from issuance of Series A Preferred Stock | — | 2 | — | — | |
| Proceeds from issuance of Series C Preferred Stock | — | 6 | — | — | |
| Proceeds from loan agreement | 3 | 1 | — | — | |
| Nonrefundable prepaid proceeds towards anticipated Series A-1 Preferred Stock Issuance | — | 3 | — | — | |
| Payment of offering costs associated with the sales agreement | −100,000 | — | — | — | |
| Proceeds from issuance of shares under the sales agreement, net of offering costs | 5 | — | — | — | |
| Capital contribution | 4 | — | — | — | |
| Net cash provided by financing activities | 12 | 12 | 4 | — | |
| Net (decrease) increase in cash | −730,623 | 230,598 | −4 | — | |
| Issuance of shares in connection with the loan agreement | 138,569 | — | — | — | |
| Conversion of convertible promissory notes into common stock in connection with Merger | — | 47 | — | — | |
| Repurchase of Series B preferred stock | — | −4 | — | — | |
| Issuance of common stock for net liabilities upon reverse recapitalization, net of transaction costs | — | 3 | — | — | |
| Right-of-use assets obtained in exchange for operating lease liabilities | 2 | — | — | — | |
| Deferred offering costs in accounts payable and accrued expenses | 104,000 | — | — | — | |
| Deferred offering cost amortization | 20,454 | — | — | — | |
| Receivables from issuance of shares under the sales agreement | 11,342 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Tevogen Bio Holdings Inc.'s CIK number?
Tevogen Bio Holdings Inc.'s SEC CIK number is 0001860871 (1860871). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Tevogen Bio Holdings Inc.'s SEC filings?
All of Tevogen Bio Holdings Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Tevogen Bio Holdings Inc. last report earnings?
Tevogen Bio Holdings Inc. (TVGNW) most recently filed an earnings 8-K with the SEC on Apr 26, 2024, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-24-016060). This is Tevogen Bio Holdings Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Tevogen Bio Holdings Inc.'s most recent earnings 8-K?
Tevogen Bio Holdings Inc.'s latest earnings 8-K (Item 2.02) was filed Apr 26, 2024 under accession 0001493152-24-016060. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Tevogen Bio Holdings Inc.'s latest earnings 8-K →
Look up any company's CIK number →